

# OUTCOMES

## Samsung Comprehensive Cancer Center

# BOOK

**E**ssential  
**C**ancer  
**H**ealth  
**O**utcomes

2026

Vol. 06



Scan to access the Outcomes Book on the Samsung Medical Center website

**SAMSUNG MEDICAL CENTER**  
Comprehensive Cancer Center



## Essential Cancer Health Outcomes

### What is ECHO?

This is more than a report—it is a commitment that reflects our core values

Essential

Cancer

Health

Outcomes

The Samsung Comprehensive Cancer Center has launched ECHO (Essential Cancer Health Outcomes), integrating its previously published cancer annual report and Outcomes Book. More than a simple acronym, ECHO embodies our commitment—grounded in the core values of Samsung Comprehensive Cancer Center to reexamine the essence of healthcare, ‘outcomes,’ from a patient-centered perspective. By transparently disclosing and systematically managing sensitive indicators such as Survival rates, mortality rates, and reoperation rates, ECHO reflects our responsibility and mission to contribute to the overall improvement of cancer care quality, extending beyond the scope of a single institution.

# Global Standards for Cancer Patient Care



In 2008,  
Samsung Comprehensive Cancer Center  
was established as Korea's first and  
largest cancer medical center.  
With the spirit of respect for life,  
the best treatment, research,  
and education have been diligently  
performed to realize healthy humanity  
and a happy life.

It has been 19 years since its  
establishment, and by publishing the 6th  
<Outcomes book>,  
Samsung Comprehensive Cancer Center  
presents the new standard of cancer  
treatment by doubling its efforts and  
seeking medical quality improvement.



# CONTENTS

---

**06**

General Director's  
Message

---

**08**

Samsung  
Comprehensive  
Cancer Center

---

**23**

Liver Cancer Center

---

**33**

Brain Tumor Center

---

**42**

Colorectal Cancer  
Center

---

**51**

Head and Neck Cancer  
Center

---

**61**

Gynecologic Cancer  
Center

---

**70**

Urologic Cancer Center

---

**84**

Gastric Cancer Center

---

**94**

Breast Cancer Center

---

**105**

Pancreatobiliary  
Cancer Center

---

**118**

Lung and Esophageal  
Cancer Center

---

**132**

Hematologic  
Malignancy Center

---

**144**

Rare Cancer Center

---

**151**

Proton Therapy Center

---

**159**

CAR T-Cell Therapy  
Center

---

**164**

Precision Oncology  
Therapeutics Center

---

**168**

Supportive Care  
Center

---

**172**

Cancer Education  
Center

---

**176**

Cancer Data Team





## Setting the Global Standard for Cancer Patient Care

When the Samsung Comprehensive Cancer Center opened in 2008, its vision was to provide truly “patient-centered care.” Moving away from the traditional physician-centered paradigm, we established a new medical culture by restructuring our entire healthcare system around the patient. Building on this patient-centered approach, multidisciplinary treatment, and the rapid adoption of the latest treatment modalities, we have grown into a world-class specialized cancer hospital.

We are now at a juncture where we must prepare for a new leap forward. As we enter an era of major transformation where cutting-edge technologies such as AI, big data, and IoT are being applied to the medical field, technologies that not only enable personalized treatment based on genetic profiles but also accurately detect even a single cancer cell and monitor patients’ conditions in real time 24 hours a day are becoming a reality. Samsung Comprehensive Cancer Center aims to realize “patient-specific lifecycle health management” based on these advanced technologies to safeguard the quality of life and happiness of patients and their families.

We are also continuing our efforts to foster mutual growth within the medical community. In 2024, we participated as the sole “nationwide model hospital” in the Ministry of Health and Welfare’s pilot project to strengthen the critical care system, and we have been designated as a “hub hospital for the remote intensive care unit (ICU) collaboration network,” expanding our care network with hospitals nationwide. We aim to realize the “Cancer Care Continuum,” in which Samsung Comprehensive Cancer Center provides care for patients with acute-phase cancer, while routine health monitoring and the prevention



and management of chronic diseases and secondary cancers are carried out through partner hospitals and clinics near the patient’s residence.

In the field of research, we will build an R&D value chain that spans from basic research to commercialization, focusing on research that directly benefits patients, research that can be rapidly integrated into clinical practice, and research conducted in collaboration with global hospitals and companies. Ultimately, our goal is to become a hospital that goes “Beyond Hospital”—that is, a hospital that not only cures diseases effectively but also cares for patients’ health and happiness with the same attentiveness as a lifelong partner.

This Clinical Quality Indicators Report(ECHO) is the fruit of the efforts our Cancer Center has dedicated to improving patient-centered healthcare quality. We hope this report serves as a meaningful milestone in establishing standards for value-based healthcare that enhances medical quality and strengthens patient safety. Moving forward, Samsung Comprehensive Cancer Center will continue to pursue world-class medical quality and strive tirelessly to provide the best possible care to every patient.


General Director of Samsung Comprehensive Cancer Center

Hee-Cheol Kim


# : 01 Core Values

## Mission, Vision and Core Values


In April 2013, we expanded our cancer center to the Comprehensive Cancer Center in an effort to provide a more specialized and comprehensive care. In 2023, we restructured our long-term strategies and vision to achieve 'Hyper-precision Medicine'.




### Core Values




### Direction of Strategy



## Strengths of Samsung Comprehensive Cancer Center



## Organizational Structure



# : 02 Milestone

**Selected by 2022-2025 Newsweek**  
**World's Best Specialized Hospitals**  
 For oncology, Ranked 1st for 4 consecutive years  
 in the Asia. 2024-2025, 3rd in the World

## 2008

- Opening of the Samsung Cancer Center(largest in Asia)
- Performed 100 robotic-assisted prostate cancer surgeries
- Successfully performed the first singleport laparoscopic surgery(SPLS) in South Korea



“Contribute to healthy and happy lives among humans by providing the best possible care, research, and education in the spirit of respect for life.”

## 2013

- Official opening of the Samsung Comprehensive Cancer Center
- Conducted the first successful 3D printer-assisted sinus cancer surgery in South Korea
- Ranked no. 1 for stomach and colon cancer, with the lowest mortality rates(HIRA)
- Designated as a research center hospital by the Ministry of Health and Welfare in 2013
- The Intractable Cancer Research Initiative identified a new mechanism of brain tumor formation for first time in the world

## 2015

- Opening of the personalized cancer care clinics at the Gastric Cancer Center
  - Performed 500 nasal-endoscopic brain tumor resections
- Suggested the personal genome analysis treatment for brain tumor for the first time in the world
  - SMC and KT signed an MOU for collaborative research on cancer genome analysis
- Genome-based personalized cancer treatment in full swing: Signed an MOU with the Translational Genomics Research Institute(TGen)

## 2010

- 30,000 cases of radiotherapy
- Korea's No. 1 clinical trial center
- The 1st Samsung Comprehensive Cancer Center symposium

## 2011

- Performed 5,000 radiofrequency heat treatments for liver cancer(the highest number of treatments in the world)
- Performed 1,000 single-port surgeries(first in South Korea)
- Ranked no. 1 for lung cancer clinical trials in South Korea
- Hosted the first international symposium

## 2012

- Performed 10,000 thoracoscopic surgeries (first in South Korea)
- Performed 5,000 gamma knife surgeries in the shortest time in South Korea
- Achieved the lowest 30-day postoperative mortality rate for stomach and colorectal cancer (Health Insurance Review and Assessment Service: HIRA)



## 2014

- Opening of the SCCC Supportive Care Center
- Performed 3,000 robotic-assisted prostate surgeries
- Performed the world's first one-stop robotic-assisted surgery for stomach and kidney cancer
- Performed 300 microvascular free-flap reconstructions for head and neck cancer
- Samsung Medical Center (SMC) and AstraZeneca signed an MOU for the clinical trials of a new anti-cancer drug for stomach cancer
  - Held the 3rd Samsung Comprehensive Cancer Center Symposium

## 2017

- Performed 10,000 lung cancer surgeries
- Treated 10,000 patients with gynecologic cancer
- Performed 10,000 laparoscopic surgeries for colorectal cancer
- Signed an MOU for collaborative research to develop a precision medicine platform for liver cancer: Agency for science, Technology and Research (A\*STAR)

## 2018

- 10th anniversary of Samsung Comprehensive Cancer Center
  - Performed 1,000 robotic-assisted nephrectomies (first in South Korea)
- Treated 1,000 patients with proton therapy
- Held the 5th Samsung Comprehensive Cancer Center Symposium

## 2021

- Opening of the CAR T-Cell Therapy Center
  - Performed 3,000 breast cancer surgeries annually at the Breast Cancer Center

## 2023

- Ranked 5th in the world for oncology by 2024 Newsweek
- Signed an MOU with Gustave Roussy Hospital, France
- Signed an MOU with Charité Comprehensive Cancer Center, Germany
  - Treated 100 patients with CAR T-cell therapy
  - Performed 20,000 gamma knife radiosurgeries
- Opening of a Dedicated Referral Desk for Samsung Comprehensive Cancer Center

## 2025

- Treated 200 patients with CAR T-cell therapy
  - Performed 100,000 proton therapy
- Ranked 3rd in the world for oncology for two consecutive years Newsweek (No. 1 in Korea, No. 1 in Asia)
  - Performed 2,000 head and neck reconstructive surgeries



## 2016

- Opening of the Proton Therapy Center
- Performed 1,000 endoscopic brain tumor surgeries
- Reached 2,000 hematopoietic stem cell transplantations for adults with hematological malignancies (first in South Korea)
- Held the 4th Samsung Comprehensive Cancer Center Symposium



## 2019

- Gastric cancer team demonstrated the effectiveness of genomic analysis personalized treatment for gastric cancer (September issue of Nature) Introduced innovative research proposals

## 2022

- Opening of the Precision Oncology Therapeutics Center
- Performed 15,000 robotic-assisted surgeries
- Held the 6th Samsung Comprehensive Cancer Center Symposium
- Performed 4,000 esophageal cancer surgeries
- Treated 5,000 patients with proton therapy

## 2024


- Ranked 3rd in the world for oncology by 2025 Newsweek
- Opening of the Institute for Quality of Life in Cancer
- Performed 2,000 liver cancer proton therapy (first in South Korea)
- Samsung Comprehensive Cancer Center Co-Hosts the Gustave Roussy International Symposium

# : 03 The SCCC Specialized Program

## Fast Track


For patients in need of prompt care, SCCC offers Fast Track that allows patients to get tested, obtain the results, and decide on a treatment plan the same day.

Unit: Case



## Face-to-face Multidisciplinary Treatment


The SCCC was the first to establish center-driven operations and a patient centered, face to face multidisciplinary care system in the country. Face-to-face multidisciplinary care for cancer patients refers to a system in which patients and their caregivers meet with specialists from three or more disciplines involved in the disease all in one location to discuss the best course of treatment, rather than having to visit multiple specialists.



## Clinical Pathway (Standard Treatment Guideline)

The SCCC established clinical pathways as the basis for patient care, and adherence to these guidelines has led to the best possible cancer outcomes.


Unit: %



## Non Face-to-face Multidisciplinary Treatment

Non-face-to-face Multidisciplinary treatment refers to a system in which multiple experts gather in one location to examine a patient's disease state in depth and discuss the best course of treatment without having to meet the patient or caregiver face-to-face.


Unit: Case



# : 04 The SCCC Patients Status


## Cancer Incidences in Korea

According to the Korea Central Cancer Registry in 2026, there were about 288,600 cancer patients in Korea in 2023. Of total 27,000 patients, which comprised about 11% of the entire cancer patient population in Korea, were treated at the Samsung Comprehensive Cancer Center.



## Distribution of Cancer Patient by Sex and Type


The distribution of patients by gender and cancer type from 2008 to 2024 showed that lung, urology and gastric cancers were most common in men, in order of incidence rate. Breast, lung and colorectal cancers were most common in women.



※ 1) Urology (prostate cancer, bladder cancer, kidney cancer) 2) Gynecology (ovarian cancer, cervical cancer)

## Distribution of Cancer Patients by Age


There are wide range of cancer patients by age at Samsung Comprehensive Cancer Center. When examining the trend since 2008, it is evident that the number of cancer patients aged 60 and above has been steadily increasing. In 2024, among the cancer patients treated at Samsung Comprehensive Cancer Center, those aged 60 and above account for 54% of the total patient population.



# : 04 The SCCC Patients Status

## Distribution of Cancer Patients by Region

Cancer patients from all over the country visit the Samsung Comprehensive Cancer Center, and about 50% of patients treated at the SCCC are from the Seoul- Gyeonggi region.




※ Address unknown 1.0%


## Treatment Status per Day

The diagnosis and treatment status of average daily cancer patients is as follows:


※ Excluding thyroid cancer and pediatrics




※ Excluding thyroid cancer and pediatrics




※ Excluding thyroid cancer and pediatrics




※ Excluding thyroid cancer and pediatrics



※ Outpatient Cancer Treatment at the Samsung Comprehensive Cancer Center




● No. of X-ray radiation therapy  
● No. of proton radiation therapy



# : 05 The SCCC Cancer Patient Survival Rates


## Survival Rates of Cancer Patients

The SCCC has an excellent reputation in the surgical treatment of early-stage cancer patients as well as in the treatment of advanced cancer patients. Through a multidisciplinary care, The SCCC provide optimal treatment for cancer patients. The 5-year Survival rates for all cancer patients treated at the SCCC is 75.4% highest in the world.




## Survival Rates by Sex

The 5-year Survival rates for male patients treat at the SCCC is 68.9%, while that for female patients is 82.5%.




## Survival Rates by Age

The 5-year Survival rates varies by age groups. The 5-year Survival rates is over 60% even for those older than 70 years of age.



## Survival Rates by Stage


The 5-year Survival rates by SEER summary stage also exceeds 91% for localized stages and 30% for distant stages.



# : 05 The SCCC Cancer Patient Survival Rates


## Cancer Specific Survival Rates by Sex

The cancer-specific 5-year Survival rates by sex for patients treated at the SCCC are as follows:



## Cancer-specific Survival Rates by Stage

The cancer-specific 5-year Survival rates by SEER stage for patients treated at the SCCC are as follows:



## 5-Year Relative Survival Rates

The results of comparing Samsung Comprehensive Cancer Center with Korea and the USA for 5-year relative survival rates provide a solid proof of our clinical excellence.


Cancer type	USA <sup>1)</sup> ('15~'21)	Korea <sup>2)</sup> ('19~'23)	SMC <sup>3)</sup> ('19~'23)
Liver	22.0	40.4	63.5
Brain and CNS	35.2	39.1	39.4
Colorectal	65.4	75.6	85.4
Lip, oral cavity, and pharynx	70.6	70.4	83.5
Cervix uteri	68.0	79.0	82.7
Ovary	51.6	66.8	68.3
Prostate	97.9	96.9	103.8
Kidney	79.7	87.9	95.4
Bladder	79.0	78.2	89.6
Stomach	37.9	78.6	89.5
Breast	91.7	94.7	97.6
Pancreas	13.3	17.0	24.6
Gallbladder and Biliary tract	21.2	29.0	39.9
Lung	28.1	42.5	65.7
Esophagus	21.9	43.5	62.5
Non-Hodgkin lymphoma	74.2	66.0	77.0

※ 1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※ Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age and sex

# : 06 Patient Experience Assessment

## Patient Experience Assessment Results


According to the Health Insurance Review and Assessment Service, Samsung Medical Center was recognized as the center of excellence in all areas of patient assessment.



※ Health Insurance Review and Assessment Service Announcement(2024)

# LIVER CANCER CENTER

- Gastroenterology
- Transplantation Surgery
- Radiology
- Radiation Oncology
- Hematology-Oncology
- Pathology and Translational Genomics
- Laboratory Medicine and Genetics
- Nuclear Medicine




The Liver Cancer Center at Samsung Medical Center will play a leading role in liver cancer treatment by developing the best possible care methods for patients with liver cancer.

# : 01 Introduction

## General Overview


The medical staff of the Liver Cancer Center, research and development of novel medical devices. We perform world-class medical care and research in all fields, including liver resection, liver transplantation, local ablation therapy, transarterial embolization, external beam radiotherapy, and systemic treatment.



# : 02 Survival Rates

## 5-Year Relative Survival Rate for Liver Cancer


The 5-year relative Survival rates of patients treated at the liver cancer center is 63.5%, which far exceeds the survival outcomes reported by other institutions.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

## 5-Year Observed Survival Rates, Liver Cancer


The 5-year Survival rates for patients treated at the Liver Cancer Center is 55.5%.



# : 03 Treatment Outcomes


## Multidisciplinary Treatment

Personalized therapy is pursued through a multidisciplinary approach to improve treatment outcomes in patients with liver cancer. Since 2016, we have been actively operating face-to-face multidisciplinary clinics and as of October 2025, we have achieved a cumulative total of 1,700 cases.




## Liver Resection

We have extensive experience in performing more than 390 liver resections per year for liver cancer patients. Recently, laparoscopic liver resection is performed in more than 88% of total cases. Moreover, laparoscopic liver resection is also actively performed in patients over 70 years of age.




## Liver Transplantation

The optimal time for liver transplantation in patients with liver cancer is determined through a multidisciplinary approach. Moreover, laparoscopic surgery is performed to ensure the safety of liver donors. Recently, liver transplantation has become possible for those with different blood types.



## Local Ablation Therapy (Radio Frequency Ablation, Microwave Ablation, Cryoablation)


Local ablation therapy is the core of minimally invasive treatment for liver cancer. Since the first experience of radiofrequency ablation (RFA) in Korea in April 1999, the liver cancer center has accumulated over 14,000 cases by September 2025. These accumulated experiences and achievements are leading the world in related treatment fields.



# : 03 Treatment Outcomes


## Transarterial Embolization

In consideration of the characteristics of the tumor, transarterial chemoembolization, drug-eluting bead transarterial chemoembolization (DEB+TACE), and radioembolization are performed. Procedures combining radiofrequency ablation or external beam radiotherapy are also actively performed.





## Systemic Therapy

Currently, we provide targeted therapy and immunotherapy to about 670 liver cancer patients annually. We offer personalized patient care through a multidisciplinary approach and NGS (Next-Generation Sequencing) testing. Various new clinical trials using novel targeted therapies and immunotherapies are currently ongoing.



## Proton Therapy


Since the opening of the Proton Therapy Center in January 2016, proton therapy has provided new hope for liver cancer patients with its excellent treatment outcomes. In 2025, it achieved a milestone of 2,400 cases of proton therapy for liver cancer patients.



# : 04 Quality Management

## Postoperative Mortality Rate


Each year, the Liver Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.



※ 1) 4th Appropriateness Evaluation Report for Liver Cancer Treatment from Health Insurance Review and Assessment Service (October 2022), (C22.0 Liver cell carcinoma, C22.1 Intrahepatic bile duct carcinoma, C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct).

## Unplanned Reoperation Rate within the Same Hospitalization Period


● No. of surgical cases (cases) ● Unplanned reoperation rate (%)



※ Excluding liver transplantation cases due to liver cancer

## Unplanned Readmission Rate within 7 Days


● No. of discharged patients ● Unplanned readmission rate (%)



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Liver Cancer Patients in Korea


In 2023, 14,707 new cases of liver cancer were reported in Korea. The Liver Cancer Center manages approximately 10.2% of these patients nationwide.



※ Excluding carcinoma in situ

## Age Distribution, Liver Cancer


Among liver cancer patients who visited the Liver Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 36.8%, and the proportion of patients aged 70 and older is steadily increasing.



# : 05 Patient Characteristics


## Sex Distribution, Liver Cancer

Among liver cancer patients who visited the Liver Cancer Center at the SCCC, 74.4% were male.



## Distress at Diagnosis, Liver Cancer

The distribution of distress levels among patients registered with liver cancer between 2014 and 2024 is presented below.



# BRAIN TUMOR CENTER

- Neurosurgery
- Radiology
- Pathology and Translational Genomics
- Radiation Oncology
- Hematology-Oncology
- Otorhinolaryngology
- Endocrinology and metabolism
- Neurology
- Physical and Rehabilitation Medicine
- Anesthesiology and Pain Medicine

The Brain Tumor Center at the Samsung Comprehensive Cancer Center provides comprehensive care for brain tumor patients with leading medical expertise and advanced technologies in Korea.

# : 01 Introduction

## General Overview


The Brain Tumor Center is pioneering personalized treatment by integrating clinical application with cutting-edge research for intractable brain tumors. We actively participate in drug development and pivotal clinical trials for the latest therapies. This offers patients expanded treatment opportunities while enabling us to lead in the rapid development and application of cutting-edge treatments.



# : 02 Survival Rates

## 5-Year Relative Survival Rate for Malignant Brain Tumor


The 5-year relative Survival rates for malignant brain tumor patients treated at the Brain Tumor Center is 39.4%, surpassing global averages.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

## 5-Year Observed Survival Rates, Malignant Brain Tumor


The 5-year observed Survival rates for malignant brain tumor patients treated at the Brain Tumor Center is 40.5%.



# : 03 Treatment Outcomes

## Research

We propose personalized, targeted treatments using tumor spheroids. By enhancing treatment accuracy through large-scale genomic and drug-response analysis of tumor spheroids, we aim to significantly improve survival outcomes and the quality of life for cancer patients.




### More Information Verification of the latest WHO classification of central nervous system tumors

The Brain Tumor Center at the Samsung Comprehensive Cancer Center reclassified intracranial solitary fibrous tumors and hemangiopericytomas into a single disease entity and reclassified them pathologically. From clinical outcome, it has been found that the 2016 WHO classification of central nervous system tumors better reflected the prognosis of the two tumors than the previous classifications system. This finding has since been incorporated into the 2021 WHO Classification of Central Nervous System Tumors (WHO CNS) and is now applied in clinical practice.


## Brain Tumor Surgery

The Brain Tumor Center performs more than 1,400 surgeries annually.



## Gamma Knife Surgery (GKS)


Since our first patient treatment in 2002, we have achieved a cumulative total of 20,000 cases as of 2023—a first in Korea. As of 2025, patients with metastatic brain tumor accounted for 53% of treatment cases.




# : 04 Quality Management

## Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Brain Tumor Center evaluates the quality of clinical services to improve quality of care and ensure a safe clinical environment.




## Unplanned Readmission Rate within 7 Days



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Malignant Brain Tumor Cases in Korea


In 2023, 2,080 new cases of malignant brain tumors were reported in Korea. The Brain Tumor Center treats approximately 16.2% of these patients nationwide.



\* Excluding carcinoma in situ

## Age Distribution, Malignant Brain Tumor


Among malignant brain tumor patients who visited the Tumor Center at the SCCC, those in their 60s accounted for the largest proportion at 27.4%.



# : 05 Patient Characteristics


## Sex Distribution, Malignant Brain Tumor

Among malignant brain tumor patients who visited the Brain Tumor Center at the SCCC, 56.7% were male.




## Age Distribution, Benign Brain Tumor

Among benign brain tumor patients who visited the Tumor Center at the SCCC, those in their 60s accounted for the largest proportion at 26.4%.




## Proportion of Newly Diagnosed Benign Brain Tumor

In 2024, 1,646 newly diagnosed patients with benign brain tumors were registered at the Brain Tumor Center.



## Sex Distribution, Benign Brain Tumor

Among benign brain tumor patients who visited the Brain Tumor Center at the SCCC, 69.0% were female.



# COLORECTAL CANCER CENTER

Colorectal Surgery

Gastroenterology

Radiology

Hematology-Oncology

Radiation Oncology

Transplantation Surgery

Thoracic Surgery


Pathology and Translational Genomics

The Colorectal Cancer Center at the Samsung Comprehensive Cancer Center leads excellence in care with advanced technologies, striving to enhance patient well-being through optimal diagnosis and surgery

## : 01 Introduction

### General Overview


The Colorectal Cancer Center has improved its treatment outcome by actively introducing high-tech treatment modalities such as robotic surgery, targeted therapy, proton therapy, and minimally invasive surgery. All departments use the common protocol based on the international guidelines to provide standardized treatment.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Colorectal Cancer


The 5-year relative Survival rates of patients treated at the Colorectal Cancer Center is 85.4%, which is a top-notch outcome compared to other cancer hospitals.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Colorectal Cancer


The 5-year observed Survival rates for patients treated at the Colorectal Cancer Center is 78.7%.



## : 03 Treatment Outcomes


### Minimally Invasive Surgery

In 2025, we performed a cumulative number of 21,000 minimally invasive surgery cases for colorectal cancer. Among the total number of colon cancer surgery, the minimally invasive surgery consisted of 90% and more. We continue to strive for more sophisticated surgery, minimal incisions, less pain, and rapid recovery.



### Chemotherapy


The number of colorectal cancer patients receiving chemotherapy has shown a steady increase, with more than 1,500 patients treated each year since 2019. We are steadily carrying out clinical trials to apply targeted therapy or immunotherapy to patients with intractable colorectal cancer who have failed in standard treatment. We make steady and persistent effort to improve the Survival rates of patients with colorectal cancer.



## : 03 Treatment Outcomes


### Proton Therapy

The Colorectal Cancer Center has performed proton therapy since 2016. The goal is to cure patients with unresectable liver metastases of colorectal cancer, previously evaluated as intractable, and recurrent rectal cancer in the pelvis, and to improve their quality of life. With this goal, the Center treats approximately 30 patients with colorectal cancer each year.



### Non-face-to-face Multidisciplinary Treatment


We provide multidisciplinary treatment for patients with refractory/recurrent colorectal cancer who have difficulty in deciding treatment plans. Several specialists from relevant departments gather together to discuss the best treatment options.




## : 04 Quality Management

### Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Colorectal Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.




### Unplanned Readmission Rate within 7 Days



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Colorectal Cancer Patients in Korea


In 2023, there were 32,610 newly diagnosed cases of colorectal cancer in Korea. The Colorectal Cancer Center manages approximately 9.7% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Colorectal Cancer

Among Colorectal Cancer patients who visited the Colorectal Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 29.4%.




## Sex Distribution, Colorectal Cancer

Among colorectal cancer patients who visited the Colorectal Cancer Center at the SCCC, 55.5% were male.



## Distress at Diagnosis, Colorectal Cancer


The distribution of distress levels among patients registered with colorectal cancer between 2014 and 2024 is presented below.



# : 05 Patient Characteristics

## Pathologic Stage Distribution of Colorectal Cancer Surgery Patients

The distribution of pathologic stages among patients who underwent surgery as their initial treatment at the Colorectal Cancer Center in 2025 is presented below.



# HEAD AND NECK CANCER CENTER


- Otorhinolaryngology- Head and Neck Surgery
- Radiation Oncology
- Hematology-Oncology
- Radiology
- Pathology and Translational Genomics
- Nuclear Medicine and Molecular Imaging
- Plastic and reconstructive Surgery
- Thoracic and Cardiovascular Surgery
- Ophthalmology
- Physical and Rehabilitation Medicine
- Neurosurgery

The Head and Neck Cancer Center strives to deliver optimal care, aiming for the highest cure rates and the best possible quality of life.

# : 01 Introduction

## General Overview


The Head and Neck Cancer Center cares about 12% of the newly registered head and neck cancer patients in Korea. As one of the major Korean hospitals, we are leading all aspects of cancer management for head and neck cancer patients in Korea, including diagnosis, treatments, and patient care.



# : 02 Survival Rates

## 5-Year Relative Survival Rate for Lip, Oral and Pharyngeal Cancer


The 5-year relative Survival rates of patients with lip, oral and pharyngeal cancer treated at the Head and Neck Cancer Center is 83.5%, which is far higher than the average worldwide.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

## 5-Year Observed Survival Rates, Lip, Oral and Pharyngeal Cancer


The 5-year observed Survival rates for Oral and Pharyngeal cancer patients treated at the Head and Neck Cancer Center is 78.0%.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Laryngeal Cancer


The 5-year relative Survival rates of laryngeal cancer patients treated at the Head and Neck Cancer Center is 88.4%, which also outperforms other hospitals.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Laryngeal Cancer


The 5-year observed Survival rates for Laryngeal cancer patients treated at the Head and Neck Cancer Center is 79.0%.



## : 03 Treatment Outcomes


### Multidisciplinary Treatment

The Head and Neck Cancer Center provides multidisciplinary treatment for 365 patients per year.



### No. of Patients Treated with Proton Therapy


In addition to early-stage disease, the center provides specialized treatment for patients with severe, intractable, and advanced-stage cancers. Since the introduction of proton therapy in 2016, 199 patients treated annually.



# : 04 Quality Management


## Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Head and Neck Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.



## Unplanned Readmission Rate within 7 Days


No. of discharged patients    Unplanned readmission rate (%)



# : 05 Patient Characteristics


## No. of Newly Diagnosed by Cancer Types

In 2024, 765 newly diagnosed patients were registered at the Head and Neck Cancer Center.



## Cancer Types


In 2023, 12% of head and neck cancer patients in Korea visited our Head and Neck Cancer Center. Patients who visited Samsung Comprehensive Cancer Center showed the following proportions: 11% oral, 17% nasal cavity, 15% salivary gland, 12% pharyngeal cancers, and 9% laryngeal cancer.



# : 05 Patient Characteristics


## Age Distribution, Lip, Oral and Pharyngeal Cancer

Among lip, oral and pharyngeal cancer patients who visited the Head and Neck Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 25.5%.




## Age Distribution, Laryngeal Cancer

Among laryngeal cancer patients who visited the Head and Neck Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 25.5%.




## Sex Distribution, Lip, Oral and Pharyngeal Cancer

Among lip, oral and pharyngeal cancer patients who visited the Head and Neck Cancer Center at the SCCC, 58.4% were male.



## Sex Distribution, Laryngeal Cancer


Among laryngeal cancer patients who visited the Head and Neck Cancer Center at the SCCC, 90.6% were male.



# : 05 Patient Characteristics


## Distress at Diagnosis, Lip, Oral and Pharyngeal Cancer

The distribution of distress levels among patients with pharyngeal cancer registered between 2014 and 2024 is presented below.



## Distress at Diagnosis, Laryngeal Cancer

The distribution of distress levels among patients with laryngeal cancer registered between 2014 and 2024 is presented below.



# GYNECOLOGIC CANCER CENTER


- Gynecologic Oncology
- Radiation Oncology
- Hematology-Oncology
- Radiology
- Pathology and Translational Genomics
- Nuclear Medicine and Molecular Imaging

Under the motto of "The First, The Best," the Gynecologic Cancer Center delivers optimal care through seamless multidisciplinary collaboration and is actively engaged in research to advance patient outcomes.

# : 01 Introduction

## General Overview


The Gynecologic Cancer Center is actively conducting research by participating in numerous multi-national, multi-institutional joint clinical trials, and is among the first to accept and standardize new treatment methods. The Center strives to develop new treatment methods by elucidating the causes of gynecologic cancer and the mechanism of therapeutic drug actions. It is continuing research to discover new targets and analyze the mechanisms and therapeutic effects of molecular target medicine to provide personalized cancer treatment.



# : 02 Survival Rates

## 5-Year Relative Survival Rate for Endometrial Cancer


The 5-year relative Survival rates of endometrial cancer patients treated at the Gynecologic Cancer Center is 89.5%, which is superior to both the national and the US.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

## 5-Year Observed Survival Rates, Endometrial Cancer


The 5-year observed Survival rates for endometrial cancer patients treated at the Gynecologic Cancer Center is 89.3%.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Cervical Cancer

The 5-year relative Survival rates of cervical cancer patients treated at the Gynecologic Cancer Center is 82.7%, which is not only the best performance outcome in the nation, but is also one of the best figures in the world



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender


### 5-Year Observed Survival Rates, Cervical Cancer

The 5-year observed Survival rates for cervical cancer patients treated at the Gynecologic Cancer Center is 82.6%.



### 5-Year Relative Survival Rate for Ovarian Cancer


Ovarian cancer is considered difficult to treat because it is often detected at an advanced stage due to the location and characteristic of tumors, thereby generally classified as a cancer with poor prognosis. The 5-year relative Survival rates of ovarian cancer patients treated at the Gynecologic Cancer Center is 68.3%, which is also among the top nationally and worldwide.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Ovarian Cancer


The 5-year observed Survival rates for ovarian cancer patients treated at the Gynecologic Cancer Center is 66.0%.




# : 03 Quality Management

## Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Gynecologic Cancer Center evaluates the quality of clinical services to maintain the high quality of care and to ensure a safe clinical environment




## Unplanned Readmission Rate within 7 Days



# : 04 Patient Characteristics

## Proportion of Newly Diagnosed Endometrial Cancer Patients in Korea


In 2023, there were 4,037 newly diagnosed cases of endometrial cancer in Korea. The Gynecologic Cancer Center manages approximately 14.7% of these patients nationwide.



\* Excluding carcinoma in situ

## Age Distribution, Endometrial Cancer


Among endometrial cancer patients who visited the Gynecologic Cancer Center at the SCCC, those in their 50s accounted for the largest proportion at 35.0%.



# : 04 Patient Characteristics

## Proportion of Newly Diagnosed Cervical Cancer Patients in Korea


In 2023, there were 3,144 newly diagnosed cases of cervical cancer in Korea. The Gynecologic Cancer Center manages approximately 13.7% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Cervical Cancer

Among cervical cancer patients who visited the Gynecologic Cancer Center at the SCCC, those in their 50s accounted for the largest proportion at 27.5%.



## Proportion of Newly Diagnosed Ovarian Cancer Patients in Korea


In 2023, there were 3,299 newly diagnosed cases of ovarian cancer in Korea. The Gynecologic Cancer Center manages approximately 11.8% of these patients nationwide.




※ Excluding carcinoma in situ

## Age Distribution of Breast Cancer Patients

Among ovarian cancer patients who visited the Gynecologic Cancer Center at the SCCC, those in their 50s accounted for the largest proportion at 30.5%.



# UROLOGIC CANCER CENTER




- Urology
- Hematology-Oncology
- Radiation Oncology
- Radiology
- Pathology and Translational Genomics
- Nuclear Medicine and Molecular Imaging

The Urologic Cancer Center is rewriting the history of urologic cancer care and shaping its future. Offering comprehensive care from A to Z, it provides the highest quality of care based on optimal treatment strategies.

## : 01 Introduction

### General Overview


The Urologic Cancer Center provides the best diagnosis and treatment based on the best medical faculties and the most advanced medical technology. We produce the best results through multidisciplinary treatment and actively perform robot assisted laparoscopic surgery, considering the quality of patient's life.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Prostate Cancer


Prostate cancer continues to increase due to a westernized diet and promotion of early screening. The 5-year relative Survival rates of prostate cancer patients treated at the Urologic Cancer Center is 103.8%, which is superior to that of the US and Korea.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender


### 5-Year Observed Survival Rates, Prostate Cancer

The 5-year observed Survival rates for prostate cancer patients treated at the Urologic Cancer Center is 90.4%.



### 5-Year Relative Survival Rate for Kidney Cancer


The 5-year relative Survival rates of kidney cancer patients is 95.4%, which is superior to that of the US and Korea.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Kidney Cancer


The 5-year observed Survival rates for kidney cancer patients treated at the Urologic Cancer Center is 89.4%.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Bladder Cancer


The 5-year relative Survival rates of bladder cancer patients is 89.6%, which is higher than that of the USA.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Bladder Cancer



The 5-year observed Survival rates for bladder cancer patients treated at the Urologic Cancer Center is 72.1%.



## : 03 Treatment Outcomes

### Local Treatment for Kidney Cancer

Radiofrequency ablation and cryotherapy for kidney cancer is limited to the patients who are sensitive to surgical therapy, the elderly patients who have difficulties in receiving surgery due to old age, and the cases where the kidney tissue needs to be preserved as much as possible. As of 2025, we have accumulated more than 1,100 clinical cases.




| Local treatment for kidney cancer (cases) |

# : 03 Treatment Outcomes


## Multidisciplinary Treatment

Through non-face-to-face multidisciplinary treatment in which specialists from 6 medical departments participate, we determine the optimal treatment plan and improve treatment outcomes. In cases of muscle-invasive bladder cancer, we run a face-to-face multidisciplinary clinic where specialists from 5 departments gather to treat and decide whether to preserve the bladder.



## Robotic Surgery (Minimally Invasive Surgery)


The Urologic Cancer Center performs more than 1,200 robotic surgeries annually, and has performed more than 11,000 surgeries cumulatively as of 2025.



# : 04 Quality Management


## Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Urologic Cancer Center evaluates the quality of clinical services to improve quality of care and ensure a safe clinical environment.



## Unplanned Readmission Rate within 7 Days


No. of discharged patients | Unplanned readmission rate (%)



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Prostate Cancer Patients in Korea


In 2023, there were 22,640 newly diagnosed cases of prostate cancer in Korea. The Urologic Cancer Center manages approximately 9.2% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Prostate Cancer

Among prostate cancer patients who visited the Urologic Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 43.9%.




## Pathologic Stage Distribution of Prostate Cancer Surgery Patients

The distribution of pathologic stages among prostate cancer patients who underwent surgery as their initial treatment at the Urologic Cancer Center in 2025 is presented below.



## Distress at Diagnosis, Prostate Cancer


The distribution of distress levels among patients with prostate cancer registered between 2014 and 2024 is presented below.



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Kidney Cancer Patients in Korea


In 2023, there were 7,367 newly diagnosed cases of kidney cancer in Korea. The Urologic Cancer Center manages approximately 11.2% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution Kidney Cancer

Among kidney cancer patients who visited the Urologic Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 31.4%.




## Sex Distribution, Kidney Cancer

Among kidney cancer patients who visited the Urologic Cancer Center at the SCCC, 68.0% were male.



## Distress at Diagnosis, Kidney Cancer


The distribution of distress levels among patients with kidney cancer registered between 2014 and 2024 is presented below.



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Bladder Cancer Patients in Korea


In 2023, there were 5,545 newly diagnosed cases of bladder cancer in Korea. The Urologic Cancer Center manages approximately 7.7% of these patients.



※ Excluding carcinoma in situ


## Age Distribution, Bladder Cancer

Among bladder cancer patients who visited the Urologic Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 35.2%.




## Sex Distribution, Bladder Cancer

Among bladder cancer patients who visited the Urologic Cancer Center at the SCCC, 79.3% were male.



## Distress at Diagnosis, Bladder Cancer

The distribution of distress levels among patients with bladder cancer registered between 2014 and 2024 is presented below.



# GASTRIC CANCER CENTER

Gastrointestinal Surgery

Gastroenterology

Hematology-Oncology

Radiation Oncology

Radiology

Pathology and Translational Genomics


Thoracic Surgery

The Gastric Cancer Center is opening a new horizon in gastric cancer care through precise diagnosis and optimal treatment, striving to enhance patient well-being.

## : 01 Introduction

### General Overview


The Gastric Cancer Center has achieved top-tier treatment outcomes across all stages of gastric cancer, backed by world-class clinical performance and expertise. The center offers personalized treatment through multidisciplinary care and maintains remarkably low recurrence rates after surgery.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Gastric Cancer


The 5-year relative Survival rates of patients treated at the Gastric Cancer Center is 89.5%, a number that is far superior to other medical institutions around the world.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-year Observed Survival rates, Gastric Cancer


The 5-year observed Survival rates for patients treated at the Gastric Cancer Center is 82.6%.



## : 03 Treatment Outcomes


### ESD Outcomes

Over the past 15 years, endoscopic submucosal dissection (ESD) for early gastric cancer has advanced significantly, with around 700 procedures performed annually, demonstrating one of the highest levels of treatment expertise in Korea.



### Gastric Cancer Surgery


Over the 5 past years, the gastric cancer center has performed more than 1,100 gastric cancer surgeries annually. The proportion of minimally invasive surgery - including laparoscopic and robotic surgery - has been steadily increasing, helping to minimize patient pain, bleeding, and scarring.




# : 03 Treatment Outcomes

## Personalized Treatment for Cancer Patients

In October 2019, we became the first in the world to demonstrate the effectiveness of genome analysis-based personalized cancer treatment. By analyzing the genomic and proteomic profiles of patients with metastatic gastric cancer, we customized targeted anticancer therapies and rapidly integrated the latest genomic analysis technologies with a multidisciplinary care system. For patients with metastatic or unresectable gastric cancer, we provide opportunities to participate in a wide range of clinical trials and deliver optimal treatment—including immunotherapy and targeted therapy—tailored to the specific characteristics of each tumor. Even in cases of advanced gastric cancer that are challenging to treat, our medical team is committed to providing the most effective individualized care. In addition, we have implemented neoadjuvant chemotherapy protocols to optimize cure rates after surgery.






	Conventional chemotherapy	Biomarker-driven treatment
266	185	85
43	46	46
8	9	9
0	6	6
0	2	2



	Conventional chemotherapy	Biomarker-driven treatment
266	78	57
8	19	19
0	3	3
0	1	1
0	1	1

## Pioneering Research Achievements in Precision Immunotherapy for Gastric Cancer

Through clinical research demonstrating the potential of precision immunotherapy in metastatic gastric cancer, we have established a scientific basis for tumor microenvironment-based personalized treatment strategies. In HER2-negative gastric cancer patients, we identified that immune cell composition is rapidly reorganized following fluorouracil/platinum chemotherapy, and that subsequent combination therapy with the immune checkpoint inhibitor pembrolizumab activates a CD8+ T cell-centered antitumor immune hub, which is closely associated with treatment responsiveness. In HER2-positive gastric cancer patients, clinical studies combining pembrolizumab after prior administration of trastuzumab revealed activation of the antibody-dependent cellular cytotoxicity (ADCC) mechanism, with particularly remarkable responses in PD-L1-positive patients. These studies, utilizing single-cell and spatial transcriptomic analyses, quantitatively characterized the heterogeneity of patient-specific immune responses. This work lays the foundation for precision medicine in gastric cancer by enabling optimal patient selection and prognostic prediction for combination regimens of immunotherapy and targeted therapy. The Gastric Cancer Center possesses analytical capabilities for profiling individual gastric cancers that are recognized as world-leading, both in Korea and internationally.




Ref) Cancer Discov. 2024 May 14(5):766-785  
Clin Cancer Res. 2025 Apr 31(8):1476-1490

# : 04 Quality Management

## Quality Management


Each year, the Gastric Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.




## | In-hospital death and 30-day postoperative mortality | | Lengthiness Index (LI) for hospitalization days |

※ LI (Lengthiness Index): An index indicating the duration of actual hospitalization compared to the expected appropriate duration of hospitalization, considering the Diagnosis-Related Group (DRG) of the nursing institution.  
 ※ Evaluation Report for Gastric Cancer Treatment from Health Insurance Review and Assessment Service (Dec 2024)

## Unplanned Reoperation Rate within the Same Hospitalization Period




## Unplanned Readmission Rate within 7 Days



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Gastric Cancer Patients in Korea


In 2023, there were 28,943 newly diagnosed cases of gastric cancer in Korea. The Gastric Cancer Center manages approximately 9.4% of these patients nationwide.



※ Excluding carcinoma in situ

## Age Distribution, Gastric Cancer


Among gastric cancer patients who visited the Gastric Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 34.9%.



# : 05 Patient Characteristics


## Sex Distribution, Gastric Cancer

Among gastric cancer patients who visited the Gastric Cancer Center at the SCCC, 65.7% were male.




## Distress at Diagnosis, Gastric Cancer

The distribution of distress levels among patients with gastric cancer registered between 2014 and 2024 is presented below.



## Pathologic Stage Distribution of Gastric Cancer Surgery Patients

The distribution of pathologic stages among gastric cancer surgery patients at the Gastric Cancer Center in 2025 is presented below.



# BREAST CANCER CENTER

Breast Surgery

Hematology-Oncology

Radiation Oncology

Plastic and Reconstructive Surgery

Obstetrics and Gynecology

Radiology

Pathology and Translational Genomics

Physical and Rehabilitation Medicine


Laboratory Medicine and Genomics

The Breast Cancer Center delivers specialized care rooted in a deep understanding of women's lives, supporting recovery and future planning. From accurate diagnosis to life after treatment, we stand by our patients at every step.

## : 01 Introduction

### General Overview


The Breast Cancer Center delivers world-class outcomes through a multidisciplinary approach involving over ten specialty departments. It offers patient-centered clinics tailored to specific needs, including young women with breast cancer, hereditary breast cancer, male breast cancer, elderly patients, and recurrent cases. The center also provides precision treatment based on the tumor's molecular and genetic characteristics.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Breast Cancer

The 5-year relative Survival rates of patients treated at the Breast Cancer Center is 97.6%, which is among the best outcomes worldwide.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rate for Breast Cancer


The 5-year observed Survival rates for patients treated at the Breast Cancer Center is 94.9%.



## : 03 Treatment Outcomes


### Young Breast Cancer Clinic

The Young Breast Cancer Clinic provides tailored breast cancer care for young women, with an understanding of their lives and daily rhythms. It supports patients not only during treatment but also as they navigate life and future planning after treatment.



### Breast Cancer Surgery


The number of breast cancer surgeries continues to increase, reaching 2,412 cases in 2025, of which 69% underwent breast-conserving surgery and 31% received total mastectomy. We actively perform oncoplastic surgery not only to remove tumors safely but also to maximize cosmetic Outcomes.



# : 03 Treatment Outcomes


## Immediate Breast Reconstruction

The number of patients undergoing total mastectomy and immediate breast reconstruction is on the rise. More than 61% of patients undergoing mastectomy receive immediate breast reconstruction.




## Radiation Therapy for Breast Cancer

Personalized radiation therapy is provided for patients with early-stage, locally advanced, and recurrent or metastatic breast cancer. High-precision hypofractionated radiation techniques are employed to enhance treatment efficiency and patient comfort.



## Multidisciplinary Breast Cancer Care

Physicians from more than ten departments meet regularly to discuss diagnosis and treatment planning for patients with breast cancer. For patients with metastatic or recurrent breast cancer, treatment decisions are made through multidisciplinary review involving radiology, pathology, medical oncology, and other specialties. Treatment planning incorporates genomic analysis and the genetic and molecular characteristics of the tumor.



## Research Activities

We are conducting various clinical trials on new treatments and novel agents for breast cancer and have published numerous SCI(E)-indexed papers through active academic research.


Unit: Cases



# : 03 Treatment Outcomes

## Translational Research in Breast Cancer Treatment



We established the world's largest Korean breast cancer cohort, comprising 1,364 patients, by integrating whole-genome sequencing and clinical data, and published the findings in Nature (IF=48.5) in December 2025. This achievement has enabled a clearer understanding of the unique characteristics and mechanisms of breast cancer in Korea, distinct from those in Western populations, and has provided a foundation for transforming the paradigm of breast cancer research and treatment. Building on these pioneering research outcomes, the Breast Cancer Center is poised to play a pivotal role in global translational breast cancer research, extending beyond Asia to the international stage.



| Comprehensive overview of the genomic and molecular characteristics of 1,364 breast cancer samples. |

## Strengthening the Network with Affiliated Hospitals


A collaborative network has been established with local medical institutions to support continuity of care for patients with breast cancer. Through this network, patients can be referred promptly for treatment and symptom management. Collaboration is maintained through regular educational programs, academic meetings, and networking activities. After surgery or systemic treatment at the Cancer Hospital, patients may be referred back to local clinics or hospitals for symptom management, follow-up care, and prescription management. Long-term breast cancer survivors may also continue follow-up care through this regional network.




# : 04 Quality Management

## Unplanned Reoperation Rate During the Same Hospitalization

The Breast Cancer Center annually evaluates and improves the quality of its medical services to ensure patient safety, maintain a comfortable care environment, and deliver the highest quality of care.




## Unplanned Readmission Rate Within 7 Days



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Breast Cancer Patients in Korea


In 2023, there were 29,871 newly diagnosed cases of breast cancer in Korea. The Breast Cancer Center manages approximately 8.6% of these patients nationwide.



\* Excluding carcinoma in situ

## Age Distribution of Breast Cancer Patients


Among breast cancer patients who visited the Breast Cancer Center at the SCCC, those in their 40s accounted for the largest proportion at 32.7%.




## : 05 Patient Characteristics

### Distress at Diagnosis, Breast Cancer

The distribution of distress levels among patients with breast cancer registered between 2014 and 2024 is presented below.



# PANCREATOBILIARY CANCER CENTER




The Pancreatic and Biliary Cancer Center is dedicated to leading the field of pancreatic and biliary cancer care, advancing optimal diagnostic and treatment strategies through continuous research and innovation.

# : 01 Introduction

## General Overview


The Pancreatobiliary Cancer Center established a patient-centered care system from diagnosis to treatment through collaborative treatment by specialists with abundant clinical experience and knowledge. The center offers optimal treatment through endoscopic management of premalignant and early-stage disease, prompt diagnosis followed by radical resection for resectable cancer, and a multidisciplinary approach for advanced disease.



# : 02 Survival Rates

## 5-Year Relative Survival Rate for Pancreatic Cancer

Pancreatic cancer is considered as the most tenacious form of malignancy, because it is often discovered at advanced stage. The 5-year relative Survival rates of pancreatic cancer patients treated in the Pancreatobiliary Cancer Center is 24.6%, which is an excellent outcome worldwide. Based on the high success rate of surgery, we strive to improve the Survival rates by actively combining surgical intervention with chemoradiotherapy.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

## 5-Year Observed Survival Rates, Pancreatic Cancer


The 5-year observed Survival rates for pancreatic cancer patients treated at the Pancreatobiliary Cancer Center is 20.8%.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Gallbladder and Biliary Tract Cancer


The 5-year relative Survival rates of gallbladder and biliary tract cancer patients treated in the Pancreatobiliary Cancer Center is 39.9%, which far outperforms the national average.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Gallbladder and Biliary Tract Cancer


The 5-year observed Survival rates for Gallbladder and Biliary Tract Cancer patients treated at the Pancreatobiliary Cancer Center is 38.8%.



## : 03 Treatment Outcomes


### Pancreatic Cancer Surgery

Pancreatic cancer surgery is a highly complex procedure that involves extensive resection, prolonged operative time, and technically demanding anastomosis. Approximately 250 pancreatic cancer surgeries are performed annually.



### Biliary Tract, Gallbladder, and Duodenum Surgery (Including benign)


We perform about 190 cases of gallbladder and biliary tract cancer surgery per year.



# : 03 Treatment Outcomes


## Proton Therapy, Pancreatic Cancer

Since initiating proton therapy in 2016, the number of patients receiving this treatment has increased annually. The Center performs 239 proton therapy for pancreatic cancer annually.




## Proton Therapy, Biliary Tract, Gallbladder, and Duodenal Cancer

Approximately 100 proton therapy for biliary tract, gallbladder, and duodenal cancers are performed annually.




## Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)

More than 690 EUS-FNA procedures are performed annually, with a steady increase over time.



## Hospitalization Days after Complicated Surgery


Although pancreatobiliary cancer surgery is complicated, the hospitalization days postsurgery are gradually decreasing due to development of surgical technique, increase in minimally invasive surgery, and complication management. It helps patients return to their daily lives quickly.



# : 04 Quality Management


## Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Pancreatobiliary Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.



## Unplanned Readmission Rate within 7 Days


No. of discharged patients, Unplanned readmission rate (%)



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Pancreatic Cancer Patients in Korea


In 2023, there were 9,748 newly diagnosed cases of pancreatic cancer in Korea. The Pancreatic and Biliary Cancer Center manages approximately 8.8% of these patients nationwide.



\* Excluding carcinoma in situ

## Age Distribution, Pancreatic Cancer


Among pancreatic cancer patients who visited the Pancreatobiliary Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 35.0%.



# : 05 Patient Characteristics


## Sex Distribution, Pancreatic Cancer

Among pancreatic cancer patients who visited the Pancreatobiliary Cancer Center at the SCCC, 57.6% were male.




## Distress at Diagnosis, Pancreatic Cancer

The distribution of distress levels among patients with pancreatic cancer registered between 2014 and 2024 is presented below.




## Pathologic Stage Distribution of Pancreatic Cancer Surgery Patients

The distribution of pathologic stages among pancreatic cancer surgery patients at the Pancreatobiliary Cancer Center in 2025 is presented below.



## Proportion of Newly Diagnosed Gallbladder and Biliary Tract Cancer Patients in Korea

In 2023, there were 7,997 newly diagnosed cases of gallbladder and biliary tract cancers in Korea. The Pancreatic and Biliary Cancer Center manages approximately 7.4% of these patients nationwide.




※ Excluding carcinoma in situ

# : 05 Patient Characteristics


## Age Distribution, Gallbladder and Biliary Tract Cancer

Among Gallbladder and Biliary Tract cancer patients who visited the Pancreatobiliary Cancer Center at the SCCC, those in their 70s accounted for the largest proportion at 37.3%.




## Sex Distribution, Gallbladder and Biliary Tract Cancer

Among Gallbladder and Biliary Tract cancer patients who visited the Pancreatobiliary Cancer Center at the SCCC, 60.0% were male.




## Distress at Diagnosis, Gallbladder and Biliary Tract Cancer

The distribution of distress levels among patients with gallbladder and biliary tract cancers registered between 2014 and 2024 is presented below.



## Pathologic Stage Distribution of Gallbladder and Biliary Tract Cancer Surgery Patients

The distribution of pathologic stages among Gallbladder and Biliary Tract cancer surgery patients at the Pancreatobiliary Cancer Center in 2025 is presented below.



# LUNG AND ESOPHAGEAL CANCER CENTER

- Pulmonary and Critical Care Medicine
- Thoracic and Cardiovascular Surgery
- Radiology
- Hematology-Oncology
- Radiation Oncology
- Nuclear Medicine and Molecular Imaging
- Gastroenterology
- Pathology and Translational Genomics
- Anesthesiology and Pain Medicine

The Lung and Esophageal Cancer Center sets a new paradigm in lung and esophageal cancer care, providing precise diagnosis and optimal treatment with outstanding surgical outcomes across both complex and minimally invasive procedures.

## : 01 Introduction

### General Overview


The Lung and Esophageal Cancer Center provides comprehensive surgical care, including complex extensive resection of locally advanced tumor and minimally invasive surgery using thoracoscopic and robotic-assisted approaches. Recently, targeted therapy and immunotherapy have been developed and their applications are being expanded. The Center leads the latest research and clinical application in this field.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Lung Cancer


The 5-year relative survival rate of patients with lung cancer in SMC is 65.7%, which is superior to national and international reference data. We maintain our top position in various metrics such as low post-surgery morbidity and mortality rates, short hospitalization periods, and reduced surgical costs.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender


### 5-Year Observed Survival Rates, Lung Cancer

The 5-year observed Survival rates for lung cancer patients treated at the Lung and Esophageal Cancer Center is 53.9%.



### 5-Year Relative Survival Rate for Esophageal Cancer


The 5-year relative survival rate of patients with esophageal cancer in SMC is 62.5%, which is superior to other cancer centers.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Esophageal Cancer


The 5-year observed Survival rates for esophageal cancer patients treated at the Lung and Esophageal Cancer Center is 55.6%.



# : 03 Treatment Outcomes


## Bronchoscopic Procedures

The Lung and Esophageal Cancer Center performs the highest number of bronchoscopic procedures in Korea, which are essential for the diagnosis and treatment of lung cancer.




## Curative Surgery for Lung Cancer

The Lung and Esophageal Cancer Center performs an average of over 1,500 curative resections annually, with more than 90% carried out using minimally invasive surgery, including robotic-assisted surgery and video-assisted thoracoscopic surgery (VATS).




## Curative Surgery for Esophageal Cancer

The Lung and Esophageal Cancer Center performs over 200 curative resections and reconstructions for esophageal cancer each year, with a rapidly increasing proportion of minimally invasive surgery, including robotic-assisted and thoracoscopic approaches.



## Endoscopic Submucosal Dissection for Early Esophageal Cancer


140 cases of endoscopic submucosal dissection (ESD) are performed annually for patients with early-stage esophageal cancer.



# : 03 Treatment Outcomes


## Chemotherapy

About 3,000 cases for non-small cell lung cancer, about 340 cases for small cell lung cancer, and about 670 cases for esophageal cancer are being treated annually.




## Radiotherapy

The Lung and Esophageal Cancer Center performs 750 courses of radiotherapy annually for non-small cell lung cancer and 76 for small cell lung cancer, as well as around 292 courses of radiotherapy for esophageal cancer each year.




## Clinical Research

The Lung and Esophageal Cancer Center is actively conducting various research aimed at improving patient outcomes.



## Research Publication


The Lung and Esophageal Cancer Center published 55 papers in 2024 and 81 in 2025, demonstrating a steady increase in research output.



## : 03 Treatment Outcomes


### Treatment Method

The Lung and Esophageal Cancer Center offers multi-modal treatment to 36.0% of our patients.



### Multidisciplinary Treatment



We provide multidisciplinary treatment for patients who have difficulty in deciding treatment plans. Several specialists from relevant departments gather together to discuss the best treatment options.



## : 04 Quality Management


### Unplanned Reoperation Rate within the Same Hospitalization Period

Each year, the Lung and Esophageal Cancer Center evaluates and improves the quality of clinical services to ensure a safe clinical environment and provide the best treatment.



### Unplanned Readmission Rate within 7 Days


● No. of discharged patients ● Unplanned readmission rate (%)



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Lung Cancer Patients in Korea


In 2023, there were 32,953 newly diagnosed cases of lung cancer in Korea. The Lung and Esophageal Cancer Center manages approximately 11.3% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Lung Cancer

Among lung cancer patients who visited the Lung and Esophageal Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 35.6%.




## Sex Distribution, Lung Cancer

Among lung cancer patients who visited the Lung and Esophageal Cancer Center at the SCCC, 63.1% were male.



## Distress at Diagnosis, Lung Cancer


The distribution of distress among patients with lung cancer registered between 2014 and 2024 is shown below.



# : 05 Patient Characteristics

## Proportion of Newly Diagnosed Esophageal Cancer Patients in Korea


In 2023, there were 3,142 newly diagnosed cases of esophageal cancer in Korea. The Lung and Esophageal Cancer Center manages approximately 22.2% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Esophageal Cancer

Among esophageal cancer patients who visited the Lung and Esophageal Cancer Center at the SCCC, those in their 60s accounted for the largest proportion at 46.3%.




## Sex distribution, Esophageal Cancer

Among esophageal cancer patients who visited the Lung and Esophageal Cancer Center at the SCCC, 86.5% were male.



## Distress at diagnosis, Esophageal Cancer

The distribution of distress among patients with lung cancer registered between 2014 and 2024 is shown below.



# HEMATOLOGIC MALIGNANCY CENTER


Hematology-Oncology  
 Radiation Oncology  
 Pathology and Translational Genomics  
 Laboratory Medicine and Genetics  
 Infectious Diseases

The Hematologic Malignancy Center aims to maintain its position as the best in Asia by providing the best treatment.

## : 01 Introduction

### General Overview


Hematologic Malignancy Center provides patients with the highest-level care through multidisciplinary collaboration. In particular, we are actively participating in international clinical researches including early clinical researches, to introduce the latest drugs that are not available yet in Korea.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Leukemia


The 5-year relative Survival rates of leukemia patients treated at the Hematologic Malignancy Center is 67.0%, which is an excellent outcome.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender


### 5-Year Observed Survival Rates, Leukemia

The 5-year observed Survival rates for leukemia patients treated at the Hematologic Malignancy Center is 61.0%.



### 5-Year Relative Survival Rate for Non- Hodgkin Lymphoma


The 5-year relative Survival rates of non-Hodgkin lymphoma is 77.0%, which is comparable to the world standards.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Non-Hodgkin Lymphoma


The 5-year observed Survival rates for Non-Hodgkin lymphoma patients treated at the Hematologic Malignancy Center is 71.3%.



## : 02 Survival Rates

### 5-Year Relative Survival Rate for Multiple Myeloma

The 5-year relative Survival rates of multiple myeloma patients is 67.5%.



※1) Surveillance Epidemiology and End Results (SEER) (2024), 2) Annual report of cancer statistics in Korea(2026), 3) Samsung Medical Center cancer statistics(2026)  
 ※Relative Survival rates is the ratio of observed Survival rates compared to the general expected Survival rates of the population group of the same age, gender

### 5-Year Observed Survival Rates, Multiple Myeloma


The 5-year observed Survival rates for Multiple myeloma patients treated at the Hematologic Malignancy Center is 57.7%.



## : 03 Treatment Outcomes


### Hematopoietic Stem Cell Transplantation (HSCT)

We have rich experience in HSCT, performing about 230 cases per year. Our nurses who specialized in oncology and who trained as transplantation coordinators, inpatient and outpatient nurses, and research nurses provide the highest level of nursing services.



### Hospitalization Days of HSCT Patients


We provide high quality medical care based on the standard guideline. The duration of hospitalization is about 22.8 days for allogeneic hematopoietic stem cell transplantation, and about 14.0 days for autologous hematopoietic stem cell transplantation.



# : 04 Patient Characteristics

## Proportion of Newly Diagnosed Leukemia Patients in Korea


In 2023, there were 4,218 newly diagnosed cases of leukemia in Korea. The Hematologic Cancer Center manages approximately 5.7% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Leukemia

Among leukemia patients who visited the Hematologic Malignancy Center at the SCCC, those in their 60s accounted for the largest proportion at 27.2%.




## Sex Distribution, Leukemia

Among leukemia patients who visited the Hematologic Malignancy Center at the SCCC, 57.6% were male.



## Distress at Diagnosis, Leukemia


The distribution of distress levels among patients with leukemia registered between 2014 and 2024 is presented below.



# : 04 Patient Characteristics

## Proportion of Newly Diagnosed Non-Hodgkin Lymphoma Patients in Korea


In 2023, there were 6,109 newly diagnosed cases of non-Hodgkin lymphoma in Korea. The Hematologic Cancer Center manages approximately 14.3% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Non-Hodgkin Lymphoma

Among Non-Hodgkin lymphoma patients who visited the Hematologic Malignancy Center at the SCCC, those in their 60s accounted for the largest proportion at 29.0%.




## Sex Distribution, Non-Hodgkin Lymphoma

Among Non-Hodgkin lymphoma patients who visited the Hematologic Malignancy Center at the SCCC, 53.9% were male.



## Distress at Diagnosis, Non-Hodgkin Lymphoma


The distribution of distress levels among patients with non-Hodgkin lymphoma registered between 2014 and 2024 is presented below.



# : 04 Patient Characteristics

## Proportion of Newly Diagnosed Multiple Myeloma Patients in Korea


In 2023, there were 2,099 newly diagnosed cases of multiple myeloma in Korea. The Hematologic Cancer Center manages approximately 9.1% of these patients nationwide.



※ Excluding carcinoma in situ


## Age Distribution, Multiple Myeloma

Among Multiple myeloma patients who visited the Hematologic Malignancy Center at the SCCC, those in their 60s accounted for the largest proportion at 41.2%.




## Sex Distribution, Multiple Myeloma

Among Multiple myeloma patients who visited the Hematologic Malignancy Center at the SCCC, 59.6% were male.



## Distress at Diagnosis, Multiple Myeloma

The distribution of distress levels among patients with Multiple Myeloma registered between 2014 and 2024 is presented below.



# RARE CANCER CENTER

Orthopedic Surgery

Transplantation Surgery

Plastic and Reconstructive Surgery

Neurosurgery

Dermatology

Gastrointestinal Surgery

Endocrine Surgery

Thoracic Surgery

Hematology-Oncology

Radiation Oncology

Pathology and Translational Genomics


Radiology

The Rare Cancer Center is leads the way in integrated solutions for rare cancer care. We will continue to deliver the Best-in-class research and care at the e forefront of rare cancer care in Korea.

## : 01 Introduction

### General Overview

The Rare Cancer Center is dedicated to treat rare cancers, which are mostly intractable, characterized by low incidence, but a high diversity of types and complex nature, making accurate diagnosis challenging. We are committed to delivering optimal care through systematic multidisciplinary approaches by our expert medical professionals and active participation in clinical trials.




Orthopedic Surgery, Transplantation Surgery, Plastic and Reconstructive Surgery, Neurosurgery, Dermatology, Gastrointestinal Surgery, Endocrine Surgery, Thoracic Surgery, Hematology-Oncology, Radiation Oncology, Pathology and Translational Genomics, Radiology

## : 02 Survival Rates


### 5-Year Observed Survival Rates for Bone and Soft Tissue Sarcoma

The 5-year observed Survival rates for bone and soft tissue sarcoma, among patients who underwent surgery for bone and soft tissue sarcoma at the Rare Cancer Center, is 80.0%.




### 5-Year Observed Survival Rates for Borderline Tumors

The 5-year observed Survival rates for borderline tumors, among patients who underwent surgery for borderline tumors at the Rare Cancer Center, is 99.1%.




### 5-Year Observed Survival Rates for Retroperitoneal Sarcoma

The 5-year observed Survival rates for retroperitoneal sarcoma, among patients who underwent surgery for retroperitoneal sarcoma at the Rare Cancer Center, is 68.1%.



### 5-Year Recurrence-free Survival Rates for Retroperitoneal Sarcoma


The 5-year recurrence-free Survival rates for retroperitoneal sarcoma, among patients who underwent surgery for retroperitoneal sarcoma at the Rare Cancer Center, is 49.3%.



# : 03 Treatment Outcomes

## Number of Multidisciplinary Reviews

The Rare Cancer Center treats more than 600 patients annually through multidisciplinary collaboration among various clinical specialists.



## Clinics

**Sarcoma Clinic**

**Target** Confirmed or suspicious sarcoma patients  
**Schedule** Monday  
**Treatment type** Outpatients/multidisciplinary treatment  
**Features** Weekly multidisciplinary discussions for patients with difficult treatment paths to determine diagnosis, therapy, and prognosis.

**Neuroendocrine Tumor Clinic**

**Target** Confirmed neuroendocrine tumor patients  
**Schedule** Ongoing  
**Treatment type** Outpatient treatment  
**Features** Accurate and rapid diagnosis/treatment; Quality of Life (QoL) management via nutrition, stress, and pain management.

**Melanoma Clinic**

**Target** Suspected/confirmed melanoma patient  
**Schedule** Wednesday  
**Treatment type** Outpatient treatment  
**Features** Simultaneous opening of outpatient treatment for melanoma diagnosis. A same-day consultation system between departments is in place.



**Gastrointestinal Stromal Tumor (GIST) Clinic**

**Target** GIST patients requiring multidisciplinary care based on lesion site/progression  
**Schedule** As needed  
**Treatment type** Outpatients / Multidisciplinary treatment  
**Features** Reduction in patient visits; accurate diagnosis and timely treatment

# : 04 Patient Reported Outcomes

## Pain



Lower pain scores indicate an improvement in the patient's quality of life. The following charts show the changes in pain scores for patients who underwent surgery for bone and soft tissue sarcoma at the Rare Cancer Center.



\* PROMIS® v1.1 -Pain Interference-Short Form 8a was used.

## Physical Function

Higher physical function scores indicate an improvement in the patient's quality of life. The following charts show the changes in physical function scores for patients who underwent surgery for bone and soft tissue sarcoma at the Rare Cancer Center.




\* PROMIS® v2.0 -Physical Function-Short Form 8b was used.

# : 04 Patient Reported Outcomes

## Depression

Lower depression scores indicate an improved quality of life. The following charts show the changes in postoperative depression scores for patients who underwent surgery for bone and soft tissue sarcoma at the Rare Cancer Center.



PROMIS® v1.0 -Emotional Distress-Depression-Short Form 8a was used.


# PROTON THERAPY CENTER

The Proton Therapy Center is pioneering a new era in cancer treatment with next-generation radiation therapy that goes beyond the limitations of conventional approaches.

# : 01 Introduction

## Features of Proton Therapy

The Proton Therapy Center provides the most advanced, next-generation radiotherapy. By utilizing the unique characteristic of the proton beam, the Bragg peak (a phenomenon that occurs when a proton beam penetrates the human body and reaches the cancer tissues; it deposits the most energy in the target location and immediately stops propagation), we can improve the accuracy and effectiveness of treatments and minimize adverse effects.



## Strengths of Proton Therapy

Higher accuracy and effectiveness with lower side effects.

### 01 Reducing adverse effects and risks of secondary cancer

- Reducing adverse effects and risks of secondary cancer by minimizing radiation exposure to the surrounding normal tissues

**Strengths**

### 02 Safe Re-irradiation

- Compared to the conventional X-ray therapy, proton therapy enables relatively safe re-irradiation.

Cardioprotective effects of proton therapy

Abdominal organ protective effect of proton therapy

# : 01 Introduction


## Differentiated Treatment

We provide accurate treatment through innovative technology, and personalized treatment based on the patient's characteristics.


1) We provide the optimal proton beam modality based on the patient's condition.

Wobbling	Scanning
Suitable for treatment of organs that move a lot due to respiration or treatment of large volume	Suitable for cases which require high precision due to the complex tumor shape and close proximity to critical normal organs

2) By using a 360-degree rotating gantry equipped with a cone-beam CT for the first time in Korea, the accuracy of dose delivery has been further improved.





3) The respiratory gating technique can minimize damage to surrounding tissues during proton therapy of tumors that move with respiration, such as liver and lung cancers. Many patients with liver cancer or lung cancer are receiving highly precise proton therapy using respiratory gating technique.



# : 02 Treatment Outcomes


## Patients Treated by Cancer Type

The number of patients treated with proton therapy is steadily increasing, with nearly 50 cases performed everyday. By cancer type, liver cancer (21.4%), brain tumor (19.4%), head and neck cancer (19.4%), and lung cancer (17.5%).




## Proton Therapy for Liver Cancer

We are the world's first institution to have achieved excellent treatment outcomes using scanning proton therapy for moving liver tumors. Currently, we have expanded the use of respiratory-gated proton therapy with scanning techniques to treat liver cancers with complex shapes.



## Proton Therapy for Pediatric Cancer



The application of proton therapy for pediatric cancer patients is increasing steadily. In addition, annually, more than 500 cases of children who have difficulty cooperating during the procedure receive proton therapy under anesthesia.



# : 02 Treatment Outcomes


## Proton Therapy for Lung Cancer

Proton therapy for advanced lung cancer demonstrates local control rates comparable to those of intensity-modulated radiation therapy (IMRT), while significantly reducing the radiation dose to the lungs.




| Comparison of radiation doses to the lungs and spinal cord in the planning of IMRT and proton therapy |

## No. of Cases for Lung Cancer Treatment



## Proton Therapy Quality Assurance Status


Prior to starting proton therapy, patient-specific pre-treatment beam delivery quality assurance is conducted. This ensures system accuracy by measuring the discrepancy between calculated and delivered doses.




# : 02 Treatment Outcomes

## Proton Therapy for Head and Neck Cancer

In oropharyngeal cancer, the rate of adverse events with Tomotherapy combined with proton therapy was significantly reduced compared to that for Tomotherapy alone.



## No. of Cases for Head and Neck Cancer Treatment



# CAR T-CELL THERAPY CENTER

- Hematology-Oncology
- Pediatrics
- Infectious Diseases
- Neurology
- Critical Care Medicine
- Cardiology
- Rheumatology

As the first personalized treatment in Korea, Samsung Comprehensive Cancer Center's CAR T-Cell Therapy proposes a new treatment paradigm for patients with relapsed or refractory hematologic malignancies.

# : 01 Introduction

## Features of CAR T-Cell Therapy


CAR T-cell therapy is frontier immunotherapy. However, before developing and introducing CAR T-cell therapy, cytotoxic chemotherapy or target agents was the prominent backbone treatment for patients with relapsed or refractory hematologic malignancies. Immunotherapy, an entirely different treatment from the previous treatment strategies, encourages activating the patient's immune system and helps fight cancer cells. Among immunotherapies, CAR T-cell therapy has been getting attention through superior efficacies and low toxicities. CAR T-cell manufacturing process generally consists of 5 steps: extracting T-lymphocytes from the patient's blood, inserting Chimeric antigen receptor (CAR) into the T-lymphocytes, and amplifying processed lymphocytes (CAR T-cells), selecting final CAR T-cell products, and administrating these cells into the patient's body. The CAR T-Cell Therapy Center is pioneering the expansion of treatment indications beyond hematologic malignancies to solid tumors, including liver and lung cancer, as well as immune diseases such as lupus. Through these efforts, the Center seeks to deliver cutting-edge precision medicine solutions to a wider patient population.



# : 01 Introduction

## Therapeutics Effects of CAR T-cell Therapy


CAR T-cell therapy has proven excellent therapeutics efficacy and extended survival outcome in patients with relapsed and refractory hematologic malignancies who have painful experiences with the previous multiple treatments. Thus, all CAR T-Cell Therapy Center team members promise to do our best to manage the patient's disease and continue to deliver hope to patients and their families.




# : 02 Treatment Outcomes

## CAR T-Cell Therapy Results

In the field of CAR T-cell therapy, we have treated 269 patients since 2021 from 2025. Efforts to improve the Survival rates of patients with relapsed, refractory, or non responsive large B-cell lymphoma continue.




## Outcomes of CAR T-Cell Therapy (Kymriah)




※2021~ 2025

† The number of patients who received bridge chemotherapy

# : 02 Treatment Outcomes



			After bridge	1M	3M	6M
PFS	5.0mo (1Y: 38%)	CR	22.5mo	16.5mo	NR	NR
		Non-CR	12.3mo	2.5mo	4.1mo	8.3mo
		P-value	0.003	<0.001	<0.001	0.003
OS	16.1mo (1Y: 58%)	CR	NR	NR	NR	NR
		Non-CR	9.8mo	9.3mo	13.8mo	NR
		P-value	0.003	<0.001	<0.001	0.157



## CAR T-Cell Therapy Contributions

- 2022.04.28 Benchmarking of CAR T-Cell Therapy Center with Asan Medical Center in Seoul
- 2022.09.27 Benchmarking of CAR T-Cell Therapy Center with Korea University Anam Hospital
- 2022.09.22 Visit by the Uzbekistan Ambassador (Benchmarking for CAR T-Cell Therapy System Establishment)
- 2023.05.24 Benchmarking of CAR T-Cell Therapy Center with Chungbuk National University Hospital
- 2023.08.03 Benchmarking of CAR T-Cell Therapy Center with Gachon University Gil Hospital
- 2024.06.24-25 Benchmarking of CAR-T Cell Therapy Center with National Taiwan University Hospital


# PRECISION ONCOLOGY THERAPEUTICS CENTER

The Precision Oncology Therapeutics Center provides the best possible care for patients with difficult-to-treat cancers through comprehensive analysis of individual patient characteristics and multidisciplinary treatment planning.

## : 01 Introduction

### General Overview

In March 2022, the treatment-oriented Precision Oncology Therapeutics Center was established; it applies genomic analysis, biomarker analysis, and immunotherapy to cancer research and clinical trials to increase the Survival rates of patients with incurable cancer and provides differentiated cancer treatment. Through personalized genomic analysis (NGS, next generation sequencing), we are ensuring that the most appropriate treatment is delivered to the individual, ultimately contributing to improved patient outcomes.




### Departments

Departments of Hematology-Oncology, General Surgery, Radiation Oncology, Gastroenterology & Hepatology, Thoracic and Cardiovascular Surgery, Pulmonary and Critical Care medicine, Nephrology, Urology, Pathology,

# : 02 Treatment Outcomes

## Establishment of Clinics at the Precision Oncology Therapeutics Center



- ① Comprehensive cancer immune mapping
- ② Early cancer detection program
- ③ Clinical integration of imaging endpoints
- ④ AI-driven prediction of treatment outcomes in clinical practice
- ⑤ Immunogenomic mapping for predicting specific complications
- ⑥ Clinical application of Proton-Immunotherapy

## Running the SMC Cure Cancer Program

**Specialized IT Development & Utilization for Precision Oncology**

- World's largest experience in genomic testing
- Integrating genomic data into clinical practice

No. of Genomic Testing Patients

**Strengthening Advanced Care through Multidisciplinary Teams**

- Leading refractory cancer treatment through ultra-precision multidisciplinary approaches
- Empowering molecular tumor board
- Establishing cancer data infrastructure
- Application of genomics-based clinical drug development

No. of MTB cases

**Clinical Application via CDW-based Registry & Dashboard Development**

- Genomic database & Visualization
- Genomic DB establishment for drug discovery & research
- Integration of genomic immunotherapy into clinical practice

**Hosting the International Forum on Precision Oncology**

- Fostering collaboration between clinicians and industry
- Building a foundation for the clinical application of advanced immunogenomic technologies

# : 03 Quality Management

## NGS DB




| ONCO Gender and Age Distribution |



| ONCO Diagnosis Distribution |




| Distribution of SNVs |



| Distribution of CNVs |



| Fusion A/B |



| ONCOPRINT |

# SUPPORTIVE CARE CENTER

- Family Medicine
- Physical and Rehabilitation Medicine
- Neuropsychiatry
- Laboratory Medicine and Genetics
- Dermatology
- Breast Surgery

The Supportive Care Center provides comprehensive care to improve cancer patients' quality of life.

## : 01 Introduction

### General Overview


The Supportive Care Center strives to assist cancer patients and their family overcome cancer and improve their quality of life. We provide personalized care to prevent and relieve the physical and psychological symptoms and adverse effects of the patients and family members during cancer treatment journey. We will lead the innovation of medical services and the implementation of comprehensive cancer treatment.



# : 01 Introduction

## Clinics

The Supportive Care Center provides what patients need through seamless cooperation among various clinics throughout the entire treatment journey.




Clinic	Treatment details
Cancer Rehabilitation Clinic	Prehabilitation, diagnosis and treatment of physical symptoms and dysfunction
Cancer Survivorship Clinic	Secondary cancer screening, and regular follow-ups, vaccination, smoking cessation, chronic disease management, treatment of long-term complications
Cancer Pain Clinic	Management of cancer pain and cancer treatment-related pain
Palliative Care Clinic	Relief of the physical symptoms and psychological/social pain for terminal cancer patients
Psycho-oncology Clinic	Alleviation of psychological symptoms such as insomnia, stress, anxiety, and depression
Genetic Clinic	Genetic counseling and diagnosis, including family members
Dermatology Clinic	Management of cancer treatment-related skin problems
Scar Clinic	Prevention and treatment of scars after cancer surgery

# : 02 Treatment Outcomes


## Number of Outpatients

29,456 patients visit the Supportive care Center annually.



## Number of Hospice Consultations

The Supportive Care Center offers specialized consultations in hospice and palliative care to facilitate advance care planning.



# CANCER EDUCATION CENTER

The Cancer Education Center provides information and psychosocial support to assist cancer patients and their caregivers throughout the cancer treatment journey.

## : 01 Introduction

### Cancer Education Center

The SCCC operates a Cancer Education Center to provide information to help cancer patients and their caregivers cope with treatment and life and to provide psychosocial support during treatment. At the Cancer Education Center, cancer education specialists provide evidence-based cancer information through a variety of educational programs and resources.



#### Providing the right information

- Cancer-specific pathfinders
- Information about rare cancers
- Cancer Information videos
- Collecting and providing cancer related educational materials from other organizations, both domestically and internationally



#### Development of cancer education materials

- Developing and delivering personalized cancer education materials for cancer patients and caregivers



#### Providing cancer education programs

- Implementing education programs for the psychosocial support of patients and caregivers → Maximizing the effectiveness of treatment and improving the quality of life



#### Providing individual counseling

- Oncology nurses are available for individual counseling for patients and caregivers

### Status of Cancer Education Materials

The Cancer Education Center provides a variety of educational resources for cancer patients and their families. In addition to booklets and leaflets, digital resources such as audiobooks are produced and distributed to improve accessibility. The current inventory of educational materials is as follows:

Type of Educational Material	Number Available
Booklets and leaflets	108
Customized information guides for rare cancers	37
Customized information guides by cancer type	8
Books	210
Audiobooks	7
Cancer-related videos	186

# : 01 Introduction

## Cancer Education Center Programs

We provide more than 30 diverse programs to support cancer patients and their caregivers throughout their treatment journey and to improve their quality of life.

### In-person education

- Preparing for Cancer Treatment
- Central Venous Catheter Care Education
- Pancreatic Cancer: 14 Things You Should Know About Diagnosis and Treatment
- Understanding Chemotherapy
- Understanding Immunotherapy
- Understanding Radiation Therapy
- Pain Management for Cancer Patients
- Social Welfare Information for Cancer Patients
- Communication Skills for Families

### Online education

#### Zoom

- Managing Skin and Nail Changes During Chemotherapy
- Managing Changes in Appearance After Chemotherapy
- Menopause and Osteoporosis Management for Cancer Patients
- Oral Care and Dental Treatment for Cancer Patients
- Cancer and Intimacy in Couples
- Can Cancer Patients Work?
- Lifestyle Guide After Breast Cancer Treatment
- Managing Stress
- Exploring My Emotions Through Art
- Understanding Life-Sustaining Treatment and Hospice Care (Advance Care Planning)

#### Youtube


- Breast Cancer: What We Didn't Have Time to Discuss in the Clinic
- Physical Activity for Cancer Patients
- Mental Health Management for Cancer Patients
- Healthy Eating After Cancer Treatment
- Weight Management for Cancer Patients
- Vaccination for Cancer Patients
- Management of Dyslipidemia and Prevention of Cardiovascular Disease in Cancer Patients



## Number of Participants in Cancer Education Programs


Over the past three years, approximately 27,000 cancer patients and caregivers have participated in the cancer education programs.

Unit: Patients




## Education Program Satisfaction

To continuously improve the quality of our cancer education programs, an annual satisfaction survey is conducted among participating patients and caregivers. In 2025, the program achieved a high satisfaction score of 4.71 out of 5.



## Reducing Length of Stay and Emergency Department Visits: Education on Peripherally Inserted Central Catheter (PICC) Care

In 2025, 1,397 patients undergoing peripherally inserted central catheter (PICC) insertion participated in the education program. This initiative aims to reduce catheter-related hospital stay and emergency department visits.



## Special Program for Cancer Patients' Return to Society

### Return-to-Work Education for Cancer Patients: "Can Cancer Patients Work? Working in a Healthy Way"

Once a week, we provides education on returning to work in a healthy manner, offering cancer patients the opportunity to explore whether they can continue working after diagnosis, when to return, and how to prepare for a successful transition back to work.

### Return-to-Work Workshop for Cancer Patients: "Back to Work: Rethinking My Work with Cancer"

On November 8, 2025, we held a workshop for cancer patients planning to return to work, helping them reflect on their lives and careers, restore a healthy work-life balance, and take the first steps back to work.

# CANCER DATA & REGISTRY




The Cancer Data Team systematically collects and curates clinical data across the entire continuum of cancer care, from diagnosis through treatment. By doing so, we foster a research ecosystem powered by high-quality data and provide a robust foundation to support evidence-based clinical decision-making.

## : 01 The SCCC Cancer Registry

### Process

The Cancer Registry for Samsung Comprehensive Cancer Center (SCCC) is being established on the purpose of prospective and accurate real-world clinical data collection. To make this complicated project possible, we introduced several new processes and systems as follows:

- 1) We introduced preliminary patient-history check-up process by the specialized nurses to accurately and systematically collect each cancer patient's basic medical history, including past and current illness record, medical prescription lists, family history, and current symptoms and signs, etc. This process will be given to all new cancer patients before clinic.
- 2) We structured and standardized the electronic medical record (EMR) forms for each cancer types for doctors to use them without increasing the work-load and without missing the valuable clinical data at the same time.
- 3) We established cancer-type specific registry in clinical data warehouse (CDW) and it is updated every day automatically.
- 4) We developed various feedback and quality control programs to continuously enhance the data accuracy, including publishing newsletters for each cancer types and regular meetings with clinicians.



### Expectation

We will provide more convenient and efficient real world big-data research environment by this innovative cancer registry system, and ultimately this effort is expected to contribute to the improvement of cancer patient treatment.



# : 01 The SCCC Cancer Registry

## Intake Interview

At the time of first visit, an expert nurse performs an interview to fill-up cancer specific history and record form. Currently, we operate PHC on patients with lung, breast, liver, colorectal, pancreatobiliary, gastric, ovarian, prostate, head and neck cancers, sarcoma, multiple myeloma, esophageal and mediastinal cancer, renal urothelial carcinoma, and uterine cancer. All cancer types will be covered soon.



**Data collected**


**Common**

Past medical history, family history, smoking history, alcohol consumption history, ECOG PS, etc.



**Disease specific**

Main symptoms (colorectal cancer, breast cancer, lung cancer), breast cancer obstetric history, liver cancer disease history, etc.


## Clinical Baseline Data Collection Rate, 2025



## Clinical Baseline Data Collection Rate, 2025




# : 01 The SCCC Cancer Registry



## EMR form and Cancer Registry

The structuring and standardization of EMR improves the accuracy and fidelity of the collected clinical data including diagnosis, staging, and current disease status (e.g., disease recurrence and/or metastasis and their specific sites). These specifically updated EMR forms for each cancer types are designed to collect valuable clinical data without increasing clinician's work load and not too-complicated for clinicians to see in the clinic. The collected data are automatically uploaded into a cancer specific registry in CDW after anonymization, laying the foundation for big data research. We completed prospective cancer registries for cancer types as follows, and the number of cancer types covered are increasing fast.



| Number of patients in the prospective cancer registry |

### Data content

<b>Basic information</b> Basic patient information, date of diagnosis, etc.	<b>Diagnosis / staging</b> Diagnosis, staging, etc.	<b>Test information</b> Blood tests, imaging tests, surgical pathology, etc.	<b>Treatment information</b> Surgery, procedures, Chemotherapy, Radiotherapy, etc.	<b>Current disease information</b> Recurrence, metastasis, death information, etc.
--	--	---	---	---

# Institute for Quality of Life in Cancer

The Institute for Quality of Life in Cancer was established in collaboration with Samsung Fire & Marine Insurance to closely track changes in risk factors and quality-of-life trends throughout the cancer care journey, and to research and develop patient-centered, integrated support strategies. With the goal of helping patients overcome physical and emotional challenges and return to daily life, we provide personalized information and intervention programs based on the latest medical evidence. Taking a fullcycle perspective—from diagnosis and treatment to recovery and beyond—the institute is dedicated to designing and supporting sustainable lives for cancer patients.

## Center for Trend sensing-risk modeling

- Analysis of cancer incidence trends and status through expert consultations
- Quarterly seminars to review the latest insights in cancer diagnosis and treatment
- Identification of diverse risk factors for chronic diseases or recurrence in cancer patients
- Generation of evidence for each patient journey using multidimensional data
- Surveys to identify unmet needs during the re-entry period, assessing physical, psychological, and social challenges faced by cancer patients

## Center for Care-Intervention Service Development

- Identify unmet needs throughout the cancer care journey and develop patient-centered, evidence-based information and interventions to improve quality of life
- Conduct qualitative research to identify unmet needs of single-person households
- Develop chemotherapy support kits and oral health kits
- Publish the casebook 'Return to Work' to support cancer patients' return to employment
- Host appearance care workshops for cancer patients
- Organize interactive YouTube Live lectures for patients
- Introduce and distribute Dior font for the visually impaired at the SCCC



# International Healthcare Center

Since 1995, SMC International Healthcare Center delivered exceptional medical care to patients from over 120 countries, establishing a global standard for healthcare excellence. Our dedicated IHC clinic operates exclusively for international patients with specialized staff providing culturally sensitive care.

## Comprehensive Services

We offer complete primary care service including preventive care, annual wellness visits, corporate health screenings, chronic and common illness management, vaccinations, and travel medicine. Specialty care is available through visiting doctors and dedicated specialty clinics, with seamless referral to SMC's advanced subspecialty departments when needed.

## Personalized Care Coordination

For patients with complex health issues or uncertainty about appropriate care, our primary care physicians conduct assessments and collaborate with you to develop comprehensive, tailored treatment plans.

## Innovative Access

Video consultations connect overseas patients with SMC physicians and their local doctors via PC or mobile platforms, and are available for patients residing outside of Korea.



**Contact** | • International Relations : support.smc@samsung.com  
• International Healthcare Center : ihs.smc@samsung.com

<b>Publisher</b>	General Director of samsung comprehensive cancer center	Hee Cheol Kim		
<b>Co-author</b>	Liver Cancer Center	Yong Han Paik	Jung Yong Hong	Harim Jung
	Brain Tumor Center	Doo-sik Kong	Kyuha Chong	Jeonga Lee
	Colorectal Cancer Center	Yongbeom Cho	Jung Kyong Shin	Youngeun Choi
	Head and Neck Cancer Center	Man Ki Chung	Nayeon Choi	EunHye Kim
	Gynecologic Cancer Center	ChelHun Choi	Yooyoung Lee	Sanghee Kim
	Urologic Cancer Center	Byong Chang Jeong	Minyong Kang	Jeil Yu
	Gastric Cancer Center	Jeeyun Lee	Taese Kim	Hye Yeon Seo
	Breast Cancer Center	Jeong Eon Lee	Haeyoung Kim	Sujin Pai
	Pancreatobiliary Cancer Center	Kwang Hyuck Lee	Hongbeom Kim	JeongMyung Han
	Lung and Esophageal Cancer Center	Hong Kwan Kim	Jaemyung Noh	Jiyoung Yoo
	Hematologic Malignancy Center	KiHyun Kim	Sangeun Yoon	MinJin Choi
	Rare Cancer Center	Sung Wook Seo	KyoWon Lee	HyunJu Ha
	Proton Therapy Center	Hee Chul Park	Sekwang Seo	Jiheey Kang
	CAR T-Cell Therapy Center	WonSeog Kim	Songmi Lee	
	Precision Oncology Therapeutics Center	SeungTae Kim	Minsuk Kwon	Mijung An
	Supportive Care Center	Dongwook Shin	Jihye Park	
	Cancer Education Center	Juhee Cho	Nayeon Kim	A Young Lee
	Cancer Data Team	Dong Hyun Sinn Yujin Bae	Sueun Kwon	Oksoon Chung Hyecheon Yu
	Office of Management and Support (Cancer Center)	Seok Jin Kim Jeong-Hyun Park Hyunsoo Kim	Jai Min Ryu HyunJung Yang Eunbin Choi	Kyungmi Yang Ji Young You Jinyoung Choi Jae sung Yoo

**Samsung Comprehensive Cancer Center  
Outcomes Book**

Vol.06

<b>Publish date</b>	March 31, 2026
<b>Published by</b>	General Director of Samsung Comprehensive Cancer Center
<b>Published at</b>	Management and support Team (Cancer Center)
<b>Website</b>	<a href="https://www.samsunghospital.com/en/about-smc/resources.do">https://www.samsunghospital.com/en/about-smc/resources.do</a>
<b>Design/production</b>	Design Han